CTLA4Ig attenuates accelerated rejection (presensitization) in the mouse islet allograft model

Transplantation. 1997 Jul 15;64(1):172-5. doi: 10.1097/00007890-199707150-00032.

Abstract

Background: Sensitization to donor antigens is a problem of growing magnitude in clinical transplantation. At a molecular level, this is due to the interaction between antigen bearing antigen-presenting cells and recipient T cells and involves both antigen presentation and co-stimulation.

Methods: Allogeneic islet transplantation was performed using DBA/2J donors and B6AF1 recipients. Four weeks before transplantation, recipient animals were given donor-specific transfusion (DST) alone, DST + CTLA4Ig, DST + control IgG, or no treatment. Graft loss was defined as a blood glucose >300 mg/100 ml.

Results: Administration of DST + control IgG 4 weeks before transplantation resulted in accelerated rejection due to presensitization (median survival time of 8 days, compared with 14.5 days for the no-treatment group). Animals treated with CTLA4Ig in combination with DST had a median survival time of 12 days, compared with 8 days for DST + IgG.

Conclusions: CTLA4Ig attenuates the tempo of accelerated rejection in this islet allograft model of presensitization, but does not prolong allograft survival as compared with no treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Abatacept
  • Animals
  • Antigens, CD
  • Antigens, Differentiation / pharmacology*
  • Blood Transfusion
  • CTLA-4 Antigen
  • Graft Rejection / prevention & control
  • Graft Survival / drug effects
  • Immunoconjugates*
  • Immunosuppressive Agents / pharmacology
  • Islets of Langerhans Transplantation / immunology*
  • Mice
  • Mice, Inbred DBA
  • Transplantation Conditioning*

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Immunoconjugates
  • Immunosuppressive Agents
  • Abatacept